AtheroGenics' AGI-1067 Pivotal Data Expected In Late Q1
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm believes a low event rate in the Phase III ARISE trial could signal a therapeutic effect of the atherosclerosis candidate, in development with AstraZeneca.